EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia

Ravi Savarirayan iD, Julie Hoover-Fong, Melita Irving, Paul Arundel, Josep Maria de Bergua, Philippe M Campeau, Toby Candler, Benjamin T Cocanougher, Valerie Cormier-Daire, Thomas Edouard, Svein O Fredwall, Paul Harmatz und 22 weitere

New England Journal of Medicine · 03.09.2026 · 395 (9) · 859-869

DOI: 10.1056/nejmoa2604565 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 03.09.2026. Verfasst von Ravi Savarirayan und 33 weiteren Autor:innen. Beteiligte Einrichtung: Murdoch Children's Research Institute, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Achondroplasia, Body Height, Receptor, Fibroblast Growth Factor, Type 3, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: BridgeBio Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AchondroplasiaBody HeightReceptor, Fibroblast Growth Factor, Type 3Tyrosine Kinase InhibitorsAdolescentChildChild, PreschoolFemaleHumansMaleAdministration, OralDouble-Blind MethodPyrimidinesPhenylurea CompoundsDrug Administration ScheduleTreatment Outcome

Substanzen

infigratinibPyrimidinesReceptor, Fibroblast Growth Factor, Type 3Phenylurea CompoundsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Johns Hopkins University, Baltimore.
  • Guy's and St. Thomas' NHS Foundation Trust, London.
  • Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.
  • Arthroscopic Surgery Unit, Medical Innovation Knowledge Sharing Hospital, Vitoria-Gasteiz, Spain.
  • Centre Hospitalier Universitaire Sainte-Justine, Montreal.

ORCID-Profile: Ravi Savarirayan, Janet M Legare

Förderung

  • BridgeBio Pharma

Zitieren

APA

Savarirayan, R., Hoover-Fong, J., Irving, M., Arundel, P., de Bergua, J. M., Campeau, P. M., Candler, T., Cocanougher, B. T., Cormier-Daire, V., Edouard, T., Fredwall, S. O., Harmatz, P., Hoernschemeyer, D., Irgens, H. U., Jamuar, S., Kannu, P., Legare, J. M., Leiva-Gea, A., McDevitt, H., …, & Rogoff, D. (2026). Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia. New England Journal of Medicine, 395(9), 859-869. https://doi.org/10.1056/nejmoa2604565

Vancouver

Savarirayan R, Hoover-Fong J, Irving M, Arundel P, de Bergua JM, Campeau PM, et al. Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia. New England Journal of Medicine. 2026;395(9):859-869. doi:10.1056/nejmoa2604565

BibTeX
@article{Savarirayan2026,
  author = {Savarirayan, Ravi and Hoover-Fong, Julie and Irving, Melita and Arundel, Paul and de Bergua, Josep Maria and Campeau, Philippe M and Candler, Toby and Cocanougher, Benjamin T and Cormier-Daire, Valerie and Edouard, Thomas and Fredwall, Svein O and Harmatz, Paul and Hoernschemeyer, Daniel and Irgens, Henrik U and Jamuar, Saumya and Kannu, Peter and Legare, Janet M and Leiva-Gea, Antonio and McDevitt, Helen and Onesimo, Roberta and Phillips, John and Del Pino, Mariana and Robinson, Marie-Eve and Rossi, Massimiliano and Skae, Mars and Ward, Leanne M and White, Klane K and Schmidt, Jane and Lystig, Ted and Salvatici, Ariana and Bai, Yun and Butler, Peter W and van Veenhuyzen, David and Rogoff, Daniela},
  title = {Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {9},
  pages = {859--869},
  doi = {10.1056/nejmoa2604565}
}
Kostenlos starten →